Open AccessP939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA‐SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐5 STUDY
Author(s) -
Nooka A.,
Lonial S.,
Grosicki S.,
Hus M.,
Song K.,
Facon T.,
Callander N. S.,
Ribrag V.,
Uttervall K.,
Quach H.,
Vorobyev V.,
Min C.K.,
Cheng S.,
Smith L. M.,
Yu J.,
Collingwood T.,
Holkova B.,
Kremer B. E.,
Gupta I. V.,
Richardson P. G.,
Minnema M. C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846624.61314.38
Subject(s) - medicine , multiple myeloma , cohort , refractory (planetary science) , adverse effect , lenalidomide , pharmacology , oncology , gastroenterology , physics , astrobiology